Tinnex

Quick links to important sections

Tinnex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tinnex

Overview of Tinnex

Tinnex is a pharmaceutical formulation containing the active ingredient Caroverine. It is primarily utilized in the management of tinnitus, a condition characterized by the perception of noise or ringing in the ears when no external sound is present.

Mechanism of Action

The therapeutic effect of Tinnex is attributed to its role as a glutamate receptor antagonist and a calcium channel blocker. In the auditory system, glutamate serves as a primary neurotransmitter. An imbalance or over-activation of glutamate receptors in the inner ear is thought to contribute to the signaling disturbances associated with cochlear tinnitus. By modulating these receptors, Caroverine aims to stabilize the neural activity within the auditory pathway.

Therapeutic Application

Tinnex is specifically indicated for cochlear synaptic tinnitus. This form of the condition is linked to functional disturbances at the synapse between the inner hair cells of the cochlea and the auditory nerve. The medication is intended to address the underlying biochemical imbalances in the inner ear rather than acting as a general sedative or masking agent.

Pharmacological Profile

As an otoneurological agent, Tinnex focuses on neuroprotection and the regulation of synaptic transmission. Its dual action helps in reducing the excitotoxicity that can damage auditory nerve fibers. The transition of the active substance through the system is designed to provide targeted support to the sensory cells of the ear.

What side effects are possible with Tinnex?

Possible Side Effects and Safety Information

Adverse reactions associated with Tinnex (Caroverine) are categorized in official regulatory documentation based on frequency and the physiological systems affected.

Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Common Nervous System: Headache, Dizziness, Fatigue. Gastrointestinal: Nausea, Dry mouth, Diarrhea, Abdominal pain.
Rare Serious allergic reactions (e.g., rash, difficulty breathing), changes in heart rhythm (arrhythmia), and psychiatric effects such as euphoria and agitation.

Commonly reported effects like dizziness and gastrointestinal disturbances are noted in regulatory reports as generally being temporary or transient.

System-Organ Classes Involved

Adverse effects are documented across several organ systems, with the most frequently cited being the Nervous System (e.g., drowsiness, blurred vision) and Gastrointestinal Disorders (e.g., vomiting). The label also notes effects on the Renal/Urinary System (e.g., urinary retention) and Cardiac System (changes in heart rate/rhythm).

Safety-Related Restrictions and Special Populations

Official prescribing information defines specific safety boundaries for use:

  • Contraindications: The medicine is explicitly restricted for use in patients with a known hypersensitivity to Caroverine and in those with acute stomach and intestinal ulcers.
  • Hepatic and Renal Impairment: Caution is advised for patients with pre-existing liver or kidney conditions (severe impairment may necessitate avoidance).
  • Pediatric Use: The medication is generally not recommended for use in children under 18 years of age due to insufficient data establishing safety and efficacy in this population.
  • Pregnancy and Lactation: Use during pregnancy or breastfeeding is generally not recommended unless deemed absolutely necessary, as safety in these populations has not been fully established in regulatory data.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Caroverine hydrochloride (Tinnex) overdose is defined by the requirement to contact emergency medical services immediately.


Documented Overdose Presentations

Specific clinical signs, symptoms, or expected physiological changes resulting from an acute overdose of Caroverine hydrochloride are not detailed in publicly accessible government regulatory documentation. Similarly, official labeling does not explicitly define specific physiological systems affected by overdose or detail associated laboratory findings. Overdose risk factors, such as specific dose levels or exposure conditions, are also not formally documented in accessible regulatory prescribing information.


Immediate Actions and When to Seek Urgent Help

Regulatory-aligned guidance mandates a singular action: seek immediate medical attention upon suspicion of any overdose. Urgent medical help is required immediately, and contact with emergency services or a visit to a hospital Emergency Department is the protocol. This mandate is consistent with the universal regulatory stance on suspected drug overdose.


Management and Supporting Information

No specific antidote, antagonist, or detailed procedural management steps (such as gastric lavage or specific monitoring protocols) are officially documented in publicly accessible government regulatory labeling for Caroverine hydrochloride. Management is therefore focused on established principles of symptomatic and supportive care. Furthermore, official labeling does not include specific overdose severity classifications or special considerations for distinct patient populations, such as the elderly or those with impaired organ function.

Therapeutic Uses of Tinnex

The therapeutic profile for caroverine is applied across domains where additional symptomatic support is needed, particularly for issues related to neurological and muscular activity. Its relevance is commonly used across conditions presenting with acute episodes of distress. It is utilized in managing both abdominal pain and tinnitus in adults.

This medicine is applied in addressing symptom clusters that may become intense or disruptive: distressing auditory sensations (ear ringing, buzzing) and discomfort related to increased muscular activity (spasms). It plays a role in managing symptoms that interfere with daily comfort and provides support that helps ease the overall symptom burden.

“The treatment is relevant in contexts involving both neurosensory symptoms and supports the patient during difficult episodes by easing distress.”

Quick Fact: Support for Auditory and Spastic Symptoms

The agent assists with maintaining functional stability, which may help ease discomfort associated with involuntary smooth muscle spasms, and contributes to improved comfort during periods of heightened symptoms related to ear ringing or buzzing.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tinnex?

The population eligibility for Tinnex (Caroverine) is strictly defined by regulatory documents, establishing who is permitted, restricted, or prohibited from using the medicine based on specific clinical factors.


Absolute Non-Eligibility (Contraindications)

Use of Caroverine is contraindicated and must be avoided by the following groups:

  • Patients with known hypersensitivity to Caroverine or any of its inactive ingredients.
  • Individuals with acute stomach and intestinal ulcers.
  • Patients with severe liver disease are instructed to avoid taking this medication.

Restricted and Age-Related Use

Population Group Regulatory Status Constraint Details
Pediatric Patients (Under 18 years) Not recommended Safety and efficacy of use not clinically established in this age group. Use is primarily for Adults (18+).
Renal/Hepatic Impairment Use with caution Patients with non-severe liver diseases or renal impairment should use the medicine under medical supervision.
Pregnancy/Lactation Not recommended Use during pregnancy and breastfeeding is discouraged unless judged absolutely necessary and the benefit outweighs the risks due to inadequate evidence.
Other Conditions Use with caution Patients with gastritis or acute voiding disorder should inform their doctor, as use may be restricted or conditional.

Official regulatory documents strictly define the eligible population for Caroverine as primarily adults, establishing absolute exclusions based on hypersensitivity and certain severe organ- or gastrointestinal-related comorbidities. Use is consistently restricted or not recommended for the pediatric population and women who are pregnant or breastfeeding, reflecting the need for established safety data in these specific populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Tinnex (Caroverine hydrochloride) based strictly on governmental regulatory prescribing information.

Interaction Scope

Official regulatory documents primarily identify a pharmacodynamic interaction involving substances that affect the central nervous system.

Category Official Regulatory Statement
Medicinal product categories with documented interactions Medicines with Central Nervous System (CNS) depressant effects (e.g., sedatives, hypnotics).
Mechanistic basis of interactions Pharmacodynamic interaction (additive or reinforced central effect).
Interaction-related restrictions Co-administration with alcohol leads to reinforcement of central effects.

Official Interaction Statements

  • Co-administration with other medicines that possess a Central Nervous System (CNS) depressant effect is documented as resulting in the reinforcement of these central effects.
  • The consumption of alcohol is formally documented to reinforce the central effects of the medicine due to its additive CNS depressant action.
  • No formally classified contraindicated combinations are explicitly listed in the regulatory summaries reviewed.
  • No explicit pharmacokinetic interactions (e.g., involving CYP enzymes or drug transporters) are documented in the regulatory summaries reviewed.

Connection to the Overall Interaction Profile

Official regulatory documents define the product’s interaction structure primarily around the risk of additive central effects when co-administered with other CNS depressants, including alcohol. The official profile is characterized by the absence of documented pharmacokinetic interaction patterns and the lack of formally designated contraindicated combinations in the reviewed prescribing information. This structure strictly outlines the known risk of pharmacodynamic reinforcement documented by regulatory authorities.

Mechanism of Action

Tinnex Mechanism of Action

Tinnex functions as a targeted molecular modulator, initiating its pharmacodynamic effect by engaging directly with defined receptor or enzyme systems. This interaction type—either binding as an agonist or an antagonist—alters the functional state of the regulatory protein, serving as the first step in the mechanistic cascade.

This binding action modifies signal transduction along defined neural or humoral pathways. Tinnex modulates the frequency and amplitude of specific cellular signaling events, thereby adjusting the propagation of chemical messages between cells. The ensuing intracellular consequences involve influencing key second-messenger systems and engaging regulatory feedback mechanisms within the pathway. The ultimate result of this mechanism is an adjustment in the pathway's intrinsic activation set point, producing changes in dynamics that characterize the system-level physiological modulation of the targeted pathways.

Dosage and Administration Information

How Tinnex is Used: Official Administration Guidelines

This section outlines the standardized administration and dosing principles for Caroverine hydrochloride (Tinnex).


Administration Scope

Instruction Entity Regulatory Guideline
Route of Administration Administered via the oral route (capsule form) or the parenteral route, specifically Intravenous (IV) or Intramuscular (IM) injection (solution form).
Dosing Schedule Oral Dosing: Individual doses typically range from 20 mg to 40 mg. The maximum total daily dose should not exceed 200 mg.
Frequency and Timing Oral Use: Administration is typically divided into three to four times daily. Parenteral Use: Administration is generally once daily.
Timing in relation to meals The oral capsule formulation may generally be taken with or without food.
Age-group rules The medicine is not typically indicated for use in children under 18 years of age, as efficacy and safety data are not established for this population.
Special procedural conditions Oral capsules must be swallowed whole and must not be broken, chewed, or crushed. The injectable form requires professional administration in a supervised clinical setting.
Course Duration Treatment often follows a defined, fixed-duration course, which can range from a multi-week period up to a multi-month continuous course.

Official Use Protocol

Official instructions require the medicine to be delivered via the Oral capsule or the Intravenous/Intramuscular injection, with the route aligning to the necessary setting. The protocol mandates that the oral capsule be administered three to four times daily, adhering strictly to the individual dose range to ensure the total intake remains below the specified daily maximum. This usage is structured as a fixed-duration regimen, not intended for indefinite maintenance. Patients must be aware that the capsule must be ingested whole to ensure proper delivery.

Recent Clinical Evidence

Tinnex: Recent Clinical Evidence

Clinical research on Tinnex (Caroverine) has primarily focused on its use in managing tinnitus, characterized by the perception of sound in the ears without an external source. The drug is categorized as a glutamate antagonist, which has been studied for its potential to modulate nerve activity in the central auditory pathways.

Overview of Efficacy Studies

Research design has typically involved randomized, placebo-controlled trials to evaluate the drug's effect in patients diagnosed with tinnitus. Studies have explored how different routes of administration (such as intravenous and oral capsule formulations) might influence outcomes.

  • Intravenous Formulation: Early single-blinded studies of the intravenous form suggested a short-term influence on tinnitus severity and grading. However, attempts to replicate these positive initial findings in subsequent trials have yielded mixed results, with some trials showing no significant sustained difference from placebo.
  • Oral Formulation: Comparative studies have been conducted, with one trial exploring the effect of oral Caroverine versus another compound, Ginkgo biloba. Both groups demonstrated improvements in Tinnitus Functional Index (TFI) scores at the end of the three-month follow-up, suggesting that both treatments were associated with a positive change in symptoms.

Safety and Tolerability Profile

Clinical trials monitor participants closely for adverse events. In published study reports, commonly reported adverse events associated with the capsule formulation included headache, nausea, and dry mouth. Some studies noted effects such as dizziness and sleepiness.

Serious events, such as cardiovascular issues, have been associated with drug discontinuation in some trial settings, although the incidence is rare. Due to the limited available data, caution is advised for use in special populations, particularly those with kidney or liver disease, and pregnant or breastfeeding women.

Frequently Asked Questions (FAQ)

Common questions about Tinnex (FAQ)


Q: Is Tinnex the same type of medicine as [similar drug name]?

Tinnex is officially classified by its dual action as a Glutamate antagonist and a non-selective Calcium channel blocker. This means its mechanism involves modulating nerve signaling and regulating the flow of calcium ions. Comparing it to other medicines requires looking at their specific pharmacological classifications and how they are described to function in official documents.


Q: What happens if I miss a time to use Tinnex?

Official information describes the general protocol for a missed oral dose, which typically involves guidance on when to use the dose or when to skip it to avoid taking a double dose. This guidance is detailed within the full prescribing information.


Q: Is Tinnex known to cause weight gain or loss?

According to official regulatory documents and the adverse reaction reports reviewed, weight gain or weight loss are not commonly listed among the frequently reported or serious side effects associated with Tinnex.


Q: Does Tinnex affect sleep patterns?

Official regulatory documents list common central nervous system effects such as drowsiness and fatigue. While the official product information notes these effects, specific details regarding generalized sleep patterns, such as insomnia or changes to sleep quality, are typically not specified beyond these known central effects.


Q: Can Tinnex be taken with common over-the-counter pain relievers?

The official interaction profile primarily highlights substances that have a Central Nervous System (CNS) depressant effect. Pain relievers that do not have this CNS depressant action are generally not listed as a formal interaction risk, but it is always noted that a healthcare provider should be informed about all co-administered products.


Q: What if I already take a vitamin or supplement—do I need to check for interactions with Tinnex?

Official patient information provides a general statement advising that patients inform their doctor or pharmacist about all medicines they are currently using. This includes any vitamins, supplements, or herbal remedies to allow the healthcare provider to assess for potential risks or interactions.


Q: Is it true that Tinnex is only for short-term use?

Official administration guidelines describe the treatment as a defined, fixed-duration course. This treatment period can range from a multi-week period up to a multi-month continuous course. The regimen is structured and not intended for indefinite or continuous maintenance use.


Q: Does Tinnex have any warnings related to driving or operating machinery?

Official documents list common effects such as dizziness and fatigue (drowsiness) that affect the nervous system. Because of these potential effects, patient information sheets often include a general caution about performing tasks like driving or operating heavy machinery until it is established how the medicine affects the individual.


Q: Are mental health changes, like anxiety or depression, listed as potential effects of Tinnex?

Official documents list rare psychiatric effects such as euphoria and agitation. While specific mood changes like anxiety or depression may not be explicitly detailed, official guidance always advises that patients report any unexpected mood or mental health changes to their healthcare provider.


Q: Is it normal to feel more tired when starting Tinnex?

Fatigue and Dizziness are listed in official regulatory reports as common effects associated with Tinnex. These effects are generally noted as being temporary or transient as the body adjusts to the medicine.


Q: Does Tinnex affect blood pressure?

The official label notes effects on the Cardiac System, including documented changes in heart rate and rhythm (arrhythmia). However, official reports do not explicitly or commonly list blood pressure changes (either hypotension or hypertension) as a frequent adverse event.


Q: Why do some people stop using Tinnex?

Data from clinical research reports indicates that some patients discontinued treatment due to experiencing adverse events. Commonly cited reasons for discontinuation include side effects such as headache, nausea, and dry mouth.


Q: Are there different strengths or types of Tinnex available?

Tinnex is formulated as a capsule for oral use and as an injection for parenteral use. Official dosing schedules indicate that individual oral doses typically range from 20 mg to 40 mg, and the available strengths for the capsule formulation are often based on this range.


Q: What should be done if someone accidentally uses too much Tinnex?

Official information consistently states that if someone is suspected of having used too much, emergency medical assistance should be sought immediately. This is the required protocol described in patient safety materials.


Q: Do patients need a special test before they can be prescribed Tinnex?

Official documents advise that the medicine should be used with caution in patients who have non-severe liver or kidney conditions. This advisory suggests that doctors may perform or require baseline tests to check the status of liver or kidney function before treatment is started.


Q: Is Tinnex known to cause stomach problems or nausea?

Yes, common gastrointestinal effects are documented in regulatory reports. These effects include Nausea, Diarrhea, Abdominal pain, and Vomiting, which are typically reported as transient.


Q: How long does the effect of Tinnex typically last after using it?

The pharmacological duration of action—the time for which the medicine remains active in the body—is a characteristic described in the official Pharmacokinetics section of the label. This section details how the body absorbs, distributes, and eliminates the drug following administration.


Q: Is it possible to become dependent on Tinnex?

Official patient safety information typically includes a statement that no habit-forming tendencies have been reported in the regulatory data reviewed.


Q: Does Tinnex work for everyone who tries it?

Studies and official information indicate that results can vary between individuals. Clinical study reports often yield mixed results and show that not all participants in trials experienced the same outcome. This indicates that the medicine does not work the same for everyone, and efficacy results can vary.


Q: Can Tinnex be used alongside herbal remedies?

Official patient safety information provides a general statement advising patients to inform their doctor or pharmacist about all herbal remedies or supplements they are currently using. This is a standard procedure described to allow the healthcare provider to evaluate the potential for interaction risks.


Q: Is there a maximum time someone can use Tinnex?

Official guidelines describe the treatment as a fixed-duration course, which places a regulatory limit on the total treatment time. This course can range from a multi-week period up to a multi-month continuous course.


Q: Does Tinnex contain common allergens like gluten or lactose?

Official patient information includes a section detailing the inactive ingredients of the medicine. This list allows patients and prescribers to determine the presence of common components like gluten, lactose, or specific dyes.


Q: Is Tinnex available without a prescription in some countries?

The legal status of the medicine, defining whether it is prescription-only or can be purchased over-the-counter, is a core piece of regulatory information. This status is formally defined by the governmental authorities in each country where the drug is approved.


Q: Are there any specific laboratory tests required while using Tinnex?

The official advisory for using the drug with caution in patients with renal or hepatic impairment suggests that monitoring of liver or kidney function tests may be required. Such monitoring may be indicated to help ensure patient safety during treatment.


Q: Is Tinnex a new medication or has it been around for a while?

Official documents describe the medicine's origin as a synthetic origin compound belonging to the Quinoxaline Derivative chemical family. This information provides context about its development history and market status.


Q: What should be reported to a healthcare provider when starting Tinnex?

Official patient information includes a section outlining what information should be communicated to the healthcare provider. This typically covers reporting pre-existing conditions, all other medicines currently being used, and any new or worsening symptoms experienced after starting treatment.


Q: What is the evidence regarding Tinnex and fatigue?

Clinical study reports detail adverse events such as fatigue and sleepiness and provide the frequency of these events as reported by participants in the trials. This data indicates that fatigue is a common, documented adverse effect.


Q: Is there an official patient leaflet or information sheet for Tinnex?

Yes, regulatory bodies mandate the provision of patient-friendly documentation for all prescription medicines. This official information, often called a Patient Information Leaflet or Medication Guide, is provided alongside the product.

How should Tinnex be stored and disposed of?

The official labeling specifies strict conditions to maintain the stability of Tinnex (Caroverine hydrochloride).

Storage Requirements

  • Temperature: Store the medicine at a temperature below 30°C.
  • Protection: Keep the product in a cool and dry place, protected away from sunlight and moisture.
  • Container and Safety: The medicine must remain in its original container, which should be tightly closed. As a mandatory precaution, Tinnex must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Tinnex must be disposed of safely. The official instructions require the medicine to be discarded in special ways, following the directions on the label or local regulations. Medicines should not be thrown into household waste or flushed down the toilet but returned to an authorized drug take-back point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tinnex found in:

A-Z Index: